ArticleFrontiers in immunology2024

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.

Yoshihiko Tasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.